Ribose (Furanose)

Ribose (Furanose)

SCHEMBL12878699

OC[C@H]1O[C@@H](O)C(O)[C@H]1O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LGALS1 P09382 2/20 0.54
LGALS3 P17931 2/20 0.54
LGALS9 O00182 1/20 0.54
LGALS8 O00214 1/20 0.54
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
GBA1 P04062 1/20 0.41
PYGB P11216 4/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL15814845 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL14349491 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL447758 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL16199379 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL24087736 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL66645 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL23017520 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL109435 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL7618455 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL13135754 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271995-A1 METHODS FOR PRODUCING DIHYDRONICOTINAMIDE RIBOSIDE FROM NICOTINAMIDE RIBOSIDE CHLORIDE NESTLE SA (CH) 2023-08-31 US disclosed
WO-2017075590-A2 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES COCRYSTAL PHARMA, INC. (US) 2017-05-04 WO disclosed
US-20170066787-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. 2017-03-09 US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-9566289-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2017-02-14 US disclosed
US-9428535-B2 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof MODERNA THERAPEUTICS, INC. (US) 2016-08-30 US disclosed
US-20160151399-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. 2016-06-02 US disclosed
US-20130130936-A1 Method of Conducting an Assay ADVANCED LIQUID LOGIC, INC. (US) 2013-05-23 US disclosed
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 US disclosed
US-20130115272-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-09 US disclosed
US-7767657-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090076142-A1 USE OF THE IRRITATING PRINCIPAL OLEOCANTHAL IN OLIVE OIL, AS WELL AS STRUCTURALLY AND FUNCTIONALLY SIMILAR COMPOUNDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-03-19 US disclosed
US-20080081905-A1 Preparation and uses of locked-ring sugar C-glycoside derivatives THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2008-04-03 US disclosed
WO-2007133908-A2 USE OF THE IRRITATING PRINCIPAL OLEOCANTHAL IN OLIVE OIL, AS WELL AS STRUCTURALLY AND FUNCTIONALLY SIMILAR COMPOUNDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-11-22 WO disclosed
WO-2007113841-A2 NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2007-10-11 WO disclosed
US-20070197460-A1 RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION ALNYLAM PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070155699-A1 Boron-containing small molecules ANACOR PHARMACEUTICALS (US) 2007-07-05 US disclosed
WO-2007053696-A2 RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION ALNYLAM PHARMACEUTICALS, INC. (US) 2007-05-10 WO disclosed
WO-2007047793-A2 CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2007-04-26 WO disclosed
US-20070000781-A1 ENZYME IMMOBILIZATION FOR ELECTROOSMOTIC FLOW RENSSELAER POLYTECHNIC INSTITUTE (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081905-A1 Preparation and uses of locked-ring sugar C-glycoside derivatives GCK, KHK, HK1 LGALS1 1508/4885LGALS3 1775/4885LGALS9 2838/4885
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 LGALS1 2323/4885LGALS3 1820/4885LGALS9 855/4885
US-20170066787-A1 BORON-CONTAINING SMALL MOLECULES ETF1, POLR1C, DPM1 LGALS1 1549/4885LGALS3 1237/4885LGALS9 1920/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 LGALS1 2323/4885LGALS3 1820/4885LGALS9 855/4885
US-20070000781-A1 ENZYME IMMOBILIZATION FOR ELECTROOSMOTIC FLOW MGAM, PNKP, AGL LGALS1 2581/4885LGALS3 1737/4885LGALS9 2344/4885
US-20160151399-A1 BORON-CONTAINING SMALL MOLECULES ETF1, POLR1C, DPM1 LGALS1 1549/4885LGALS3 1237/4885LGALS9 1920/4885
US-20070197460-A1 RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION SNRPE, EIF2AK2, AGO2 LGALS1 2442/4885LGALS3 2338/4885LGALS9 2622/4885
US-20090076142-A1 USE OF THE IRRITATING PRINCIPAL OLEOCANTHAL IN OLIVE OIL, AS WELL AS STRUCTURALLY AND FUNCTIONALLY SIMILAR COMPOUNDS OXER1, TRPA1, NR1H3 LGALS1 4004/4885LGALS3 4106/4885LGALS9 4308/4885
US-20230271995-A1 METHODS FOR PRODUCING DIHYDRONICOTINAMIDE RIBOSIDE FROM NICOTINAMIDE RIBOSIDE CHLORIDE NRDC, NAMPT, NNT LGALS1 4807/4885LGALS3 4814/4885LGALS9 4654/4885
US-20070155699-A1 Boron-containing small molecules ETF1, POLR1C, DPM1 LGALS1 1549/4885LGALS3 1237/4885LGALS9 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.